Loading
Sentiment · FY2026 Q2
| Analyst | Firm | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Pito Chickering | Deutsche Bank | 21 (19%) |
| Andrew Mok | Barclays | 15 (13%) |
| A.J. Rice | UBS | 14 (7%) |
| Kevin Fischbeck | Bank of America | 13 (8%) |
| Ryan Langston | TD Cowen | 12 (0%) |
| Justin Lake | Wolfe Research | 10 (20%) |
| Joanna Gajuk | Bank of America | 3 (33%) |
| Firm | Analysts | Questions (Challenge)Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Deutsche Bank | 1 | 21 (19%) |
| Bank of America | 3 | 17 (12%) |
| Barclays | 1 | 15 (13%) |
| UBS | 1 |
DaVita raised FY2026 adjusted OI guidance midpoint from $2.16 billion to $2.20 billion on volume strength and cost outperformance, with Q1 adjusted EPS of $2.87 representing 44% year-over-year growth. Treatment volume inflected positive with treatments per normalized day up 40 basis points as Fresenius transfers and early mortality improvements contributed. IKC delivered its strongest CKCC results to date while ACA enrollment trended better than feared.
Demand | Subscriber Growth | Revenue Growth | Pricing | Innovation & R&D | Regulation Policy | Margin | Guidance Reliability | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 3 | 1 | 3 | 2 | 2 | 2 | 2 | 2 |
| 2025Q1 | 2 | 2 | 4 | 1 | 2 | 2 | 1 | 2 |
| 2025Q2 | 4 | 4 | 4 | 1 | 2 | 1 | 2 | 1 |
| 2025Q3 | 5 | 5 | 2 | 3 | 1 | 2 | 1 | 2 |
| 2025Q4 | 4 | 2 | 1 | 3 | 5 | 2 | 2 | 1 |
| 2026Q1 | 4 | 3 | 2 | 3 | 1 | 2 | 2 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | |
|---|---|---|---|---|---|---|
| Demand | 3 | 2 | 4 | 5 | 4 | 4 |
| Subscriber Growth | 1 | 2 | 4 | 5 | 2 | 3 |
| Revenue Growth | 3 | 4 | 4 | 2 | 1 | 2 |
| Pricing | 2 | 1 | 1 | 3 | 3 | 3 |
| Innovation & R&D | 2 | 2 | 2 | 1 | 5 | 1 |
| Regulation Policy | 2 | 2 | 1 | 2 | 2 | 2 |
| Margin | 2 | 1 | 2 | 1 | 2 | 2 |
| Guidance Reliability | 2 | 2 | 1 | 2 | 1 |
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $3.29B | +4.7% | $3.09 | +90.7% | 17.2% | 7.9% | $377M |
| FY2025 Q1 | $3.22B | +5.0% | $2.00 | -24.5% | 13.6% | 5.1% | $37M |
| FY2025 Q2 | $3.38B | +6.1% | $2.58 | +3.2% | 15.9% | 5.9% |
| 14 (7%) |
| TD Cowen | 1 | 12 (0%) |
| Wolfe Research | 3 | 12 (17%) |
| $203M |
| FY2025 Q3 | $3.42B | +4.8% | $2.04 | -18.4% | 14.8% | 4.4% | $675M |
| FY2025 Q4 | $3.62B | +9.9% | $2.45 | -20.7% | 15.2% | 6.5% | $395M |
| FY2026 Q1 | $3.42B | +6.0% | $2.87 | +43.5% | 14.1% | 5.8% | $219M |
| FY2026 Q2 | $3.55B | +5.2% | $4.02 | +55.8% | 16.1% | 7.5% | $320M |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
What DVA and other companies said about each other on FY2026 Q1 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“primarily as the result of no longer recognizing losses from our investment in Mozarc.”
DaVita stopped recognizing losses from its investment in Mozarc (its home-dialysis technology joint venture), improving other income.
“which includes the shares bought from Berkshire Hathaway pursuant to our repurchase agreement.”
DaVita repurchased shares from Berkshire Hathaway, its largest shareholder, under a standing repurchase agreement.
“Census also benefited from patient transfers in related to ongoing clinic closures by Fresenius.”
DaVita is gaining dialysis patients transferring in from clinics that competitor Fresenius is closing, a tailwind DaVita expects to add to treatment growth over the year.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
DVA DaVita | 7 | +6.0% | |
| HCA HCA Healthcare | 6 | +4.3% | |
| SOLV Solventum | 6 | -3.0% | |
| UHS Universal Health Services | 7 | +9.7% |